Bulk Paclitaxel - Global Strategic Business Report - Product Image

Bulk Paclitaxel - Global Strategic Business Report

  • ID: 338490
  • Report
  • Region: Global
  • 232 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • Hospira, Inc. (USA) .
  • Indena S.p.A. (Italy)
  • MORE
This report analyzes the worldwide markets for Bulk Paclitaxel in kilograms and US$ Million. The report provides separate comprehensive analytics for the US, and Rest of World. Annual forecasts are provided for the period of 2000 through 2015. The report profiles 35 companies including many key and niche players worldwide such as Abraxis BioScience, Inc., Bioxel Pharma, Inc., Bristol-Myers Squibb Co., Hospira, Inc., Indena S.p.A., OncoGenex Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Xechem International Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Hospira, Inc. (USA) .
  • Indena S.p.A. (Italy)
  • MORE
BULK PACLITAXEL

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. Executive Summary

1. Industry Overview II-1
Paclitaxel - Leading from the Front II-1
US Market - Magnificently Outdistancing Others II-1
Cancer Blockbusters - Facing the Brunt II-1
A Sunrise Opportunity II-1
BMS’ Reign Comes to an End II-2
Exploring New Avenues II-2
Falling Prices - Boon for The Customers, Bane for The Companies II-2
All the Strangle for Peanuts? II-3
Factors Affecting the Market II-3
Paclitaxel Versus Abraxane II-3

2. Outlook II-5
Bulk Paclitaxel - Great Future Ahead II-5
Competitive Scenario II-5
Cancer Generics - A Time for Optimism II-5
The US Piazza II-6

3. Product Overview II-7
Chemical Properties II-7
Sourcing II-7
From Natural Sources II-8
Yew Trees II-8
From Semi-Synthesis Process II-8
Mechanism of Action II-8
History of Paclitaxel and its Discovery as an Anti-Cancer Agent II-9
China Wins Laurels for Supply of Natural Paclitaxel II-10
Hazelnut Trees Emerge as the Alternate Source of Paclitaxel II-10
Taxol - The Uncrowned Leader II-11
Paclitaxel - Concerns II-11
Abraxane and Tocosol: Set to Ride the Market Duel? II-11
Many Faces (Phases) of Paclitaxel - The Variants II-12
Taxotere - A Potential Competitor to Paclitaxel II-12

4. Research and Development II-13
Angiotech Unfurls New Dimensions for Paclitaxel II-13
Clinical Research Favors Paclitaxel for Breast Cancer Treatment II-13
American BioScience’ Nab Technology Unveils Higher Tissue
Penetration Potential II-13
Naturol Develops Unique Extraction Technology for Producing
Paclitaxel from Canadian Yew II-14
Ivax Corp.’s Xorane Revolutionizes the Delivery of Paclitaxel II-14

5. Product Launches/Introductions II-15
Dabur Launches Cancer Drug. II-15
Dabur Introduces Nanoxel. II-15
Nippon Introduces Paclitaxel Injection NK. II-15

6. Recent Industry Activity II-16
Sonus to Merge with OncoGenex II-16
Acusphere Signs Licensing Deal with Cephalon II-16
Sonus Terminates TOCOSOL Paclitaxel Development Program II-16
Eagle Pharmaceuticals to Develop and Market Tocosol Paclitaxel II-16
Pliva Lachema Receives ANDA for Paclitaxel Injection II-16
Cell Therapeutics Receives EMEA Acceptance II-17
Abraxis Wins Approval for ABRAXANE in Korea II-17
Boston Scientific Obtains Approval for TAXUS Liberte from
Health Canada . II-17
Cell Therapeutics Renames Xyotax as Opaxio II-17
Hospira Takes Over Mayne Pharma II-17
Protherics to Acquire MacroMed II-17
Abraxis Acquires Arizona Production Facility II-18
Indena Inks Worldwide License Agreement with Spectrum Pharma II-18
Bioxel Bags Major Paclitaxel Order II-18
Bioxel Enters into Supply Agreement II-18
Bioxel Bags Paclitaxel Supply Contract II-19
Indena Establishes New Plant to Produce Synthetic Paclitaxel II-19
Abraxis Selects Korean Green Cross to Market ABRAXANE II-19
Abraxis Grants License to Biocon for Marketing ABRAXANE II-19
Bioxel Registers Docetaxel with US FDA II-19
Bayer Quashes TOCOSOL Paclitaxel License with Sonus II-20
Abraxis’ ABRAXANE Convinces European CHMP II-20
Abraxis Receives Approval for ABRAXANE in Australia II-20
Eurocor Receives CE Mark II-20
SuperGen Divests Certain Drugs to Intas II-20
Abraxis Plans Separation of Oncology Business II-20
Teva Acquires IVAX II-21
Mayne to Acquire Nipent and SurfaceSafe Product Rights in
North America II-21
Athersys Expands Research Collaboration with Bristol-Myers
Squibb II-21
American Pharmaceutical Partners and American BioScience
Combine to Create Abraxis BioScience II-22
Bioxel Increases its Presence in Europe II-22
Xechem Resolves Paclitaxel Antitrust Lawsuit with Bristol-
Myers Squibb II-22
Angiotech Acquires American Medical Instruments II-22
Paxis Signs Supply Agreement for Europe and the United States II-22
Angiotech to Take Over Quill Medical II-22
Bioxel and Cook Enters Supply Agreement for Paclitaxel II-23
Angiotech Acquires Lifespan Vascular Graft Business II-23
Bristol-Myers Extends Agreement with Ambit II-23
Angiotech Takes Over Afmedica II-23
Bristol-Myers Squibb Gets European Approval for Paclitaxel II-23
Angiotech Signs Exclusive License Agreement with CABG Medical II-24
Conor Medsystems Acquires the Assets of Phytogen Life Sciences II-24
Sonus Pharmaceuticals and Schering Sign Licensing Agreement. II-24
Sonus’ Tocosol Wins FDA’s ODD II-24
ABI’s Abraxane Wins FDA Approval II-25
SuperGen’s Paclitaxel Injection Accorded ANDA Status from the
USFDA II-25
Ivax Signs Agreement with Mayne II-25
Integrated Bio Pharma Acquires Hauser CRO II-25
Mayne Gearing up to Fight it Alone with Proprietary Paclitaxel II-25
Bioxel Inks a Paclitaxel Supply Deal with CTI II-25
DFB Pharmaceuticals Takes Over Phyton II-25
NaPro Divests Paclitaxel Business to Faulding II-26
Bioxel-Aerojet’s Large-Scale Paclitaxel Purification Process
Gets FDA’s Nod II-26
Ivax Earns Expanded Approval for Paxene from the European
Commission II-26
Sonus Obtains Third Patent for the Composition of Tocosol
Paclitaxel II-26
Bioxel Forays into the European Market II-26
Xechem Pockets Additional Patents for Second Generation
Paclitaxel II-27
Dabur Pharma Initiates Phase IIb Trial for Nanoparticle
Delivery Systems II-27
Acusphere Inc. Completes Phase 1 Trial for AI-850 II-27
Tisorex Changes Name to Paxis Pharmaceuticals II-27

7. Focus on Select Global Players II-28
Abraxis BioScience, Inc. (USA) II-28
Bioxel Pharma Inc. (Canada) II-28
Bristol-Myers Squibb Co. (USA) II-28
Hospira, Inc. (USA) . II-28
Indena S.p.A. (Italy) II-29
OncoGenex Pharmaceuticals, Inc. (USA). II-29
Teva Pharmaceuticals USA, Inc. (USA) . II-29
Xechem International Inc. (USA) II-30

8. Global Market Perspective II-31
Table 1: World Recent Past, Current & Future Analysis for
Bulk Paclitaxel by Geographic Region - US and Rest of World
Markets Independently Analyzed with Annual Sales in Kilograms
for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-31

Table 2: World Long-term Projections for Bulk Paclitaxel by
Geographic Region - US and Rest of World Markets Independently
Analyzed with Annual Sales in Kilograms for Years 2011 through
2015 (includes corresponding Graph/Chart) II-32

Table 3: World Recent Past, Current & Future Analysis for Bulk
Paclitaxel by Geographic Region - US and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) II-33

Table 4: World Long-term Projections for Bulk Paclitaxel by
Geographic Region - US and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-34

Table 5: World 10-Year Perspective for Bulk Paclitaxel by
Geographic Region - Percentage Breakdown by Volume Sales for
US and Rest of World Markets for Years 2003, 2008, & 2012 II-35

Table 6: World 10-Year Perspective for Bulk Paclitaxel by
Geographic Region - Percentage Breakdown by Dollar Sales for
US and Rest of World Markets for Years 2003, 2008, & 2012 II-35

III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Rising Demand for Paclitaxel III-1
Alarming Growth of Breast Cancer III-1
Clinical Research Favors Paclitaxel for Breast Cancer
Treatment III-1
Paclitaxel - An Important Element III-2
Corporate Talk III-2
Drug-Eluting Stents - Marching Ahead III-2
Strategic Corporate Developments III-2
Key Players III-7
B.Market Analytics III-10
Table 7: US Recent Past, Current & Future Analysis for Bulk
Paclitaxel Market with Annual Sales in Kilograms for Years
2000 through 2010 (includes corresponding Graph/Chart) III-10

Table 8: US Long-term Projections for Bulk Paclitaxel
Market with Annual Sales in Kilograms for Years 2011
through 2015.(includes corresponding Graph/Chart) III-10

Table 9: US Recent Past, Current & Future Analysis for Bulk
Paclitaxel Market with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding
Graph/Chart) III-11

Table 10: US Long-term Projections for Bulk Paclitaxel
Market with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-11

2. Rest of World III-12
A.Market Analysis III-12
Current and Future Analysis III-12
Europe. III-12
European Market Overview III-12
European Market Battling Cost-Containment Woes III-12
Efforts to Improve the Scenario and their Effect on
Paclitaxel Market III-13
China. III-13
Chinese Government Strategizing to Save Paclitaxel Reserves III-13
Product Launches/Developments. III-13
Strategic Corporate Development III-14
Key Players III-20
B.Market Analytics III-22
Table 11: Rest of World Recent Past, Current & Future
Analysis for Bulk Paclitaxel Market with Annual Sales in
Kilograms for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-22

Table 12: Rest of World Long-term Projections for Bulk
Paclitaxel with Annual Sales in Kilograms for Years 2011
through 2015 (includes corresponding Graph/Chart) III-22

Table 13: Rest of World Recent Past, Current & Future
Analysis for Bulk Paclitaxel Market with Annual Sales in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-23

Table 14: Rest of World Long-term Projections for Bulk
Paclitaxel Market with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding
Graph/Chart). III-23

IV. COMPETITIVE LANDSCAPE
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abraxis BioScience, Inc. (USA)
  • Bioxel Pharma Inc. (Canada)
  • Bristol-Myers Squibb Co. (USA)
  • Hospira, Inc. (USA) .
  • Indena S.p.A. (Italy)
  • OncoGenex Pharmaceuticals, Inc. (USA).
  • Teva Pharmaceuticals USA, Inc. (USA) .
  • Xechem International Inc. (USA)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll